Last reviewed · How we verify
Drug: Carfilzomib + Lenalidomide + Dexamethasone
This three-drug combination kills multiple myeloma cells by inhibiting the proteasome, enhancing immune response to tumor cells, and suppressing tumor-promoting inflammation.
This three-drug combination kills multiple myeloma cells by inhibiting the proteasome, enhancing immune response to tumor cells, and suppressing tumor-promoting inflammation. Used for Relapsed or refractory multiple myeloma, Newly diagnosed multiple myeloma.
At a glance
| Generic name | Drug: Carfilzomib + Lenalidomide + Dexamethasone |
|---|---|
| Also known as | Kyprolis |
| Sponsor | Amgen |
| Drug class | Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination |
| Target | 20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Carfilzomib is a proteasome inhibitor that blocks protein degradation in cancer cells, triggering apoptosis. Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activity while also having direct anti-proliferative effects. Dexamethasone is a corticosteroid that provides additional anti-inflammatory and anti-proliferative activity. Together, these agents work synergistically to overcome drug resistance and improve outcomes in multiple myeloma.
Approved indications
- Relapsed or refractory multiple myeloma
- Newly diagnosed multiple myeloma
Common side effects
- Anemia
- Thrombocytopenia
- Neutropenia
- Fatigue
- Diarrhea
- Nausea
- Peripheral neuropathy
- Dyspnea
- Cardiac toxicity
- Hyperglycemia
Key clinical trials
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- KRDI in Transplant-Eligible MM (PHASE2)
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma (PHASE1, PHASE2)
- Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (PHASE3)
- Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma (PHASE4)
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma (PHASE1)
- Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction (PHASE2)
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: